ENTA
Enanta Pharmaceuticals Inc
Halal Rating :
Last Price
$5.25
Last updated:
Market Cap
-
7D Change
4.37%
1 Year Change
-55.47%
Company Overview
Industries
Exchange
Next Earnings Date
Enanta Pharmaceuticals Inc is a biotechnology company focused on using chemistry-driven approaches to create small molecule drugs for viral infections and liver diseases. The company's research and development pipeline includes clinical programs for respiratory syncytial virus (RSV), hepatitis B virus (HBV), and SARS-CoV-2 (COVID-19).
Their revenue primarily comes from royalties on sales of products containing glecaprevir, which is part of AbbVie's hepatitis C virus (HCV) treatment regimens.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $14.61m | $47.04m | - | $2.58m | 0.00% | 5.49% |
| June 30, 2024 | $17.97m | $44.51m | - | $2.35m | 0.00% | 5.29% |
| March 31, 2024 | $17.05m | $52.38m | - | $2.56m | 0.00% | 4.89% |
Company Impact
Help us evaluate Enanta Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.